MAP2K7 and lung cancer: Since MEK inhibitors and CDK4/6 inhibitors kill lung cancers and, at the same time, induce a re-population of NK cells, it has been suggested that an activated MEK/ERK axis impairs the immune-surveillance mediated by NK cells [147], further contributing to induce an immune-evasive mechanism.